BioMarin’s Amicus Synergy Timeline Shifts, Voxogo Switching Claims Don’t Match

Date of Call: Aug 6, 2026

Financials Results

• Revenue: Nearly $1 billion, up 20% year-over-year
• EPS: $1.20 per diluted share (non-GAAP)
• Operating Margin: 36.4% (non-GAAP)

Guidance:

• Raised full-year 2026 total revenue guidance, ROXOGO revenue, and non-GAAP diluted EPS guidance.
• Q3 revenue expected slightly higher than Q2; Q4 revenue expected to be strongest, representing well over 50% of second-half revenue.
• Q3 non-GAAP EPS expected slightly higher than Q2; Q4 non-GAAP EPS expected significantly higher, representing highest quarterly earnings of the year.
• Voxogo revenue guidance raised to path to become first $1 billion product.
• Expect substantial non-GAAP EPS accretion beginning in 2027 from Amicus integration and synergies.

Business Commentary:

Revenue Growth and Integration of Amicus:

• BioMarin reported nearly $1 billion in revenue for Q2 2026, marking a 20% year-over-year increase.
• This growth was driven by the successful close and integration of Amicus, contributing to a more diversified portfolio and setting up a stronger second half of 2026.

Voxogo's Market Performance:

• Voxogo achieved 14% year-over-year revenue growth in Q2, with double-digit growth both in the U.S. and internationally.
• The increase in Voxogo's full-year guidance, positioning it on a path to become BioMarin's first $1 billion product, is attributed to strong demand and effective defense against a U.S. competitor.

Amicus Acquisition and Synergies:

• The acquisition of Amicus is projected to contribute significantly to BioMarin's growth trajectory, with peak revenue potential estimated at $2.6 billion from Gallifold and Pombility and Opfolder combined.
• The anticipated $220 million in annual cost synergies by 2028, representing a 50% reduction from Amicus's 2025 operating expenses, is expected to drive substantial EPS accretion and operating cash flow.

Pipeline and New Indications:

• BioMarin advanced pivotal pipeline data towards Voxogo's next indication, with a supplemental NDA submission for hypochondriplasia.
• The rapid submission timeline, aided by AI capabilities, reflects BioMarin's execution efficiency and sets a new standard for future operations.

Sentiment Analysis:

Overall Tone: Positive

• CEO called it a "standout second quarter," highlighted "20% top-line growth," "successful close and integration of Amicus," "advancing pivotal data," and "strong demand" allowing guidance increase. Management expressed confidence in long-term growth and leadership in rare diseases.

Q&A:

• Question from Chris Raymond (Raymond James): Could you give waypoints on achieving 2028 synergies and steps to delever one year early? Also, on Voxogo, can you provide dynamics on competition for new patients?
  Response: For Amicus, synergies are being executed via comprehensive integration plan; ~half realized in 2027, full in 2028, driving accretion. Regarding Voxogo, competitor switch rate is ~10% (~<100 patients), retaining ~90% of U.S. patients; new patient starts remain strong globally; guidance raised due to performance and growth.

• Question from Corey Casimo (Evercore ISI): How do you view the combination of weekly CNP analog plus growth hormone in treatment algorithm and potential use with Voxogo or BMN 333?
  Response: The small COACH study data suggests growth hormone effects may be waning when added to CNP; long-term impact on final adult height and safety (e.g., growth plate closure) remain unanswered; watching data closely; no immediate plans to change treatment approaches.

• Question from Jess Pye (JPMorgan): Will Amicus synergies drop to bottom line or be reinvested?
  Response: Synergies will drop to the bottom line, but modest reinvestment will accelerate growth of acquired assets; reinvestment is part of normal P&L, not an offset to synergies.

• Question from Salveen Richter (Goldman Sachs): How do diagnosis and switching strategies differ U.S. vs. ex-U.S. for Gallifold and Pompility/Opfolder? What is appetite for future BD?
  Response: Strategies are similar globally, focused on increasing diagnosis for Fabry and accelerating switches for Pompe. For BD, focus is on expanding clinical-stage pipeline in genetic conditions leveraging BioMarin's capabilities; expect deals in next 12-18 months.

• Question from Phil Natto (TD Cowan): Any update on ITC case and thoughts on settlement? Why have late-onset and female Fabry patients not been diagnosed more quickly?
  Response: ITC timeline provided; no speculation on strategy/outcomes. For Fabry diagnosis, disease is elusive with heterogeneous presentation; efforts include technology, EHRs, family cascade testing to shorten time to diagnosis.

• Question from Ellie Merle (Barclays): What trends/characteristics in Voxogo switchers? What is U.S. incidence for under-two age group?
  Response: Switchers cite injection fatigue/preference for weekly therapy; 90% retention driven by strong evidence base and patient services. U.S. annual births with achondroplasia estimated ~150; targeting early treatment in maternal fetal medicine.

• Question from Mohit Mansal (Wells Fargo): Where do you expect U.S. switch rate to settle? How does ex-U.S. market differ in competitiveness?
  Response: Not quantifying future switch expectations; monitoring closely. Ex-U.S. market is more segmented and geographically dispersed, which may affect competitive dynamics differently.

• Question from Akesh Tiwari (Jefferies): What market work done for hypochondriplasia and expected bolus at approval?
  Response: Hypochondriplasia addressable population ~14,000 globally; working on diagnosis, genetic reclassification, and awareness campaigns; preparing for launch with pre-approval implementation science to reach patients quickly.

• Question from Paul Matisse (Stiefel): What BD scope? What optimal pipeline size?
  Response: BD focused on genetic conditions leveraging BioMarin's capabilities; looking for clinical-stage assets in metabolic/cellular conditions and other genetic areas; expect steady flow over next 12-18 months; pipeline depth enhanced by Amicus acquisition.

• Question from Sean Lehman (Morgan Stanley): How much of $2.6B peak revenue is market acceleration vs. BioMarin adding value? What is BMN 333 enrollment rate and next signpost?
  Response: Value addition comes from expanding diagnosis (Gallifold) and accelerating switches (Pompility/Opfolder), not changing prevalence. For BMN 333, enrollment is active globally; next update expected after Phase 2 completion, with Phase 3 data anticipated in 2027.

• Question from Alex Hammond (Wolf Research): Does guidance bump relate more to growth or switching? How does BMN 333's seamless design accelerate timeline?
  Response: Guidance raise driven by both switching and growth (U.S. and international), including favorable pricing outcomes. For BMN 333, seamless design accelerates Phase 3 recruitment via regulatory efficiencies and patient readiness.

Contradiction Point 1

Amicus Synergy Realization Timeline and Financial Impact

Timeline for full synergy realization and its EPS impact shifts from 2028 to 2027.

Does Chris Raymond from Raymond James have a question? - Chris Raymond (Raymond James)

2026Q2: The first full year of benefits driving the accretion and deleveraging. By 2028, ~50% of synergies are expected to be realized. - [Brian Mueller](CFO)

Can you outline the Amicus integration synergy roadmap through 2027, including key steps and the rationale for accelerating deleveraging by one year? - Chris Raymond (Raymond James)

2026Q2: Approximately half of the $220M annual synergies are expected to be realized in 2027, with full realization in 2028. - [Brian Mueller](CFO)

Contradiction Point 2

Voxogo Competitive Dynamics and Switching Rate

Differing characterizations of competitor impact and patient switching trends.

Chris Raymond (Raymond James) - Chris Raymond (Raymond James)

2026Q2: On Voxogo, the competitor's patient enrollment figure includes naive patients and discontinuations, making the switch rate the key metric. BioMarin's data shows only ~10% of U.S. patients have switched (~<100 patients) in ~6 months, a small impact on ~$4B annual revenue. - [Alexander Hardy](CEO)

Given that ~90% of U.S. patients remain on therapy, how do competitive dynamics impact new patient enrollment for Voxogo? - Tommie Reerink (Goldman Sachs)

2026Q1: Demand remains strong. New patient enrollments in Q1 exceeded the average for the second half of 2025 and continued into April. - [Cristin Hubbard](CCO)

Contradiction Point 3

Amicus Integration Synergies and Deleveraging Timeline

Inconsistency regarding the expected timeline for achieving synergies and deleveraging.

Chris Raymond (Raymond James) - Chris Raymond (Raymond James)

2026Q2: The deal is expected to be modestly dilutive in 2026 (close to break-even) and accretive starting in 2027, with substantial synergies beginning to be realized in 2028. By 2028, ~50% of synergies are expected to be realized, with the first full year of benefits driving the accretion and deleveraging. - [Brian Mueller](CFO)

Can you outline the 2027 milestones for Amicus integration synergies, the steps to achieve them, and the rationale for accelerating deleveraging by one year? - Paul Matteis (Stifel)

2026Q1: For 2026, the acquisition is slightly dilutive to EPS, becomes accretive in the first 12 months post-close, and substantially accretive from 2027 onward. - [Brian Mueller](CFO)

Contradiction Point 4

Competitive Dynamics and Voxogo Switching Rate

Contradiction on the significance and impact of competitor data versus BioMarin's reported patient retention.

Chris Raymond (Raymond James) - Chris Raymond (Raymond James)

2026Q2: On Voxogo, the competitor's patient enrollment figure includes naive patients and discontinuations, making the switch rate the key metric. BioMarin's data shows only ~10% of U.S. patients have switched (~<100 patients) in ~6 months, a small impact on ~$4B annual revenue. - [Alexander Hardy](CEO)

Regarding Amicus integration synergies, can you provide the pathway to 2027 synergies, steps to achieve them, and the rationale for the accelerated deleveraging, and for Voxogo competition, can you offer insights on competitive dynamics for new patients considering the ~90% retention rate? - Chris Raymond (Raymond James)

20260224-2025 Q4: Switching dynamics are limited currently, as patients doing well are unlikely to switch. Long-term safety/efficacy data will be decisive for switchers. - [Cristin Hubbard](CCO)

Contradiction Point 5

Market Outlook for Newborn Screening and Diagnosis

Contradiction on the primary growth driver for the Voxogo market—early treatment versus newborn screening.

Sean Lehman (Morgan Stanley) - Sean Lehman (Morgan Stanley)

2026Q2: For Galliford, the biggest contribution is expected from opening up diagnosis (e.g., via newborn screening, family testing). For Pombility, it's accelerating patient switching. - [Kristen Hubbard](CCO)

What portion of the $2.6B peak revenue target for Galliford and Pombility by the mid-2030s is attributed to market acceleration versus BioMarin's contributions, and what factors support this confidence? - Mohit Bansal (Wells Fargo)

20260224-2025 Q4: Early treatment is key, and Voxzogo's label allows for early starts. Switching dynamics are limited currently, as patients doing well are unlikely to switch. - [Cristin Hubbard](CCO)